NADPH oxidase 4 attenuates cerebral artery changes during the progression of marfan syndrome

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 310, Issue 9, 2016, Pages H1081-H1090

  Onetti, Yara ^a   Meirelles, Thayna ^b   Dantas, Ana P ^c   Schröder, Katrin ^d   Vila, Elisabet ^a   Egea, Gustavo ^b,c   Jiménez Altayó, Francesc ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Fibrillin 1; Neurovascular disorders; Nox4; Transforming growth factor

Indexed keywords

COLLAGEN; ELASTIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSFORMING GROWTH FACTOR BETA; FBN1 PROTEIN, MOUSE; FIBRILLIN 1; NOX4 PROTEIN, MOUSE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKENING; ARTICLE; AUTOREGULATION; BRAIN ARTERY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; MALE; MARFAN SYNDROME; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ARTERIAL PRESSURE; CEREBROVASCULAR DISORDERS; COMPLICATION; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; MECHANICAL STRESS; MECHANOTRANSDUCTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; TIME FACTOR; VASCULAR REMODELING;

ANIMALS; ARTERIAL PRESSURE; CEREBROVASCULAR DISORDERS; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FIBRILLIN-1; GENETIC PREDISPOSITION TO DISEASE; MALE; MARFAN SYNDROME; MECHANOTRANSDUCTION, CELLULAR; MICE, KNOCKOUT; MIDDLE CEREBRAL ARTERY; NADH, NADPH OXIDOREDUCTASES; NADPH OXIDASE; PHENOTYPE; REACTIVE OXYGEN SPECIES; STRESS, MECHANICAL; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR REMODELING; VASCULAR STIFFNESS;

EID: 84983761028     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00770.2015     Document Type: Article

References (51)

1. Arribas SM, Hillier C, González C, McGrory S, Dominiczak AF, McGrath JC. Cellular aspects of vascular remodeling in hypertension revealed by confocal microscopy. Hypertension 30: 1455–1464, 1997.
2. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13: 968–972, 1989.
3. Blomfield J, Farrar JF. The fluorescent properties of maturing arterial elastin. Cardiovasc Res 3: 161–170, 1969.
4. Briones AM, Arribas SM, Salaices M. Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens 19: 187–194, 2010.
5. Canadas V, Vilacosta I, Bruna I, Fuster V. Marfan syndrome. Part 1: pathophysiology and diagnosis. Nat Rev Cardiol 7: 256–265, 2010.
6. Carmona-Cuenca I, Roncero C, Sancho P, Caja L, Fausto N, Fernández M, Fabregat I. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 49: 965–976, 2008.
7. Chung AW, Au Yeung K, Cortes SF, Sandor GG, Judge DP, Dietz HC, van Breemen C. Endothelial dysfunction and compromised eNOS/ Akt signaling in the thoracic aorta during the progression of Marfan syndrome. Br J Pharmacol 150: 1075–1083, 2007a.
8. Chung AW, Au Yeung K, Sandor GG, Judge DP, Dietz HC, van Breemen C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res 101: 512–522, 2007b.
9. Chung AW, Yang HH, van Breemen C. Imbalanced synthesis of cyclooxygenase-derived thromboxane A2 and prostacyclin compromises vasomotor function of the thoracic aorta in Marfan syndrome. Br J Pharmacol 152: 305–312, 2007c.
10. Conway JE, Hutchins GM, Tamargo RJ. Marfan syndrome is not associated with intracranial aneurysms. Stroke 30: 1632–1636, 1999.
11. Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler Thromb Vasc Biol 35: 911–917, 2015.
12. Crosas-Molist E, Meirelles T, López-Luque J, Serra-Peinado C, Selva J, Caja L, Del Blanco DG, Uriarte JJ, Bertran E, Mendizábal Y, Hernández V, García-Calero C, Busnadiego O, Condom E, Toral D, Castella M, Forteza A, Navajas D, Sarri E, Rodríguez-Pascual F, Dietz HD, Fabregat I, Egea G. Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome. Arterioscler Thromb Vasc Biol 35: 960–972, 2015.
13. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. NADPH oxidase 4 mediates transforming growth factorbeta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900–907, 2005.
14. Cui JZ, Tehrani AY, Jett KA, Bernatchez P, van Breemen C, Esfandiarei M. Quantification of aortic and cutaneous elastin and collagen morphology in Marfan syndrome by multiphoton microscopy. J Struct Biol 187: 242–253, 2014.
15. Dammanahalli JK, Wang X, Sun Z. Genetic interleukin-10 deficiency causes vascular remodeling via the upregulation of Nox1. J Hypertens 29: 2116–2125, 2011.
16. Dantas AP, Onetti Y, Oliveira MA, Carvalho MH, Heras M, Vila E, Jiménez-Altayó F. Western diet consumption promotes vascular remodeling in non-senescent mice consistent with accelerated senescence, but does not modify vascular morphology in senescent ones. Exp Gerontol 55: 1–11, 2014.
17. Dietz HC, Cutting CR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francomano CA. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352: 337–339, 1991.
18. Dikalov S, Griendling KK, Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 49: 717–727, 2007.
19. Doyle JJ, Gerber EE, Dietz HC. Matrix-dependent perturbation of TGFβ signaling and disease. FEBS Lett 586: 2003–2015, 2012.
20. Drummond GR, Sobey CG. Endothelial NADPH oxidases: which NOX to target in vascular disease? Trends Endocrinol Metab 25: 452–463, 2014.
21. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 66: 8–17, 1990.
22. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 15: 1077–1081, 2009.
23. Hu JH, Wei H, Jaffe M, Airhart N, Du L, Angelov SN, Yan J, Allen JK, Kang I, Wight TN, Fox K, Smith A, Enstrom R, Dichek DA. Postnatal deletion of the type II transforming growth factor-β receptor in smooth muscle cells causes severe aortopathy in mice. Arterioscler Thromb Vasc Biol 35: 2647–2656, 2015.
24. Jiménez-Altayó F, Martín A, Rojas S, Justicia C, Briones AM, Giraldo J, Planas AM, Vila E. Transient middle cerebral artery occlusion causes different structural, mechanical, and myogenic alterations in normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 293: H628–H635, 2007.
25. Johnson AC, Cipolla MJ. The cerebral circulation during pregnancy: adapting to preserve normalcy. Physiology (Bethesda) 30: 139–147, 2015.
26. Judge DP, Dietz HC. Marfan’s syndrome. Lancet 366: 1965–1976, 2005.
27. Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ. NADPH oxidases in vascular pathology. Antioxid Redox Signal 20: 2794–2814, 2014.
28. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, Ferruzzi J, Kim RW, Geirsson A, Dietz HC, Offermanns S, Humphrey JD, Tellides G. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest 124: 755–767, 2014.
29. Loeys BL. Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders? Drug Discov Today 20: 262–266, 2015.
30. Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, Papaharalambus C, Lassègue B, Griendling KK. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 105: 249–259, 2009.
31. Maiellaro-Rafferty K, Weiss D, Joseph G, Wan W, Gleason RL, Taylor WR. Catalase overexpression in aortic smooth muscle prevents pathological mechanical changes underlying abdominal aortic aneurysm formation. Am J Physiol Heart Circ Physiol 301: H355–H362, 2011.
32. Miller AA, Drummond GR, Schmidt HH, Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 97: 1055–1062, 2005.
33. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGFbeta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407–411, 2003.
34. Novensa L, Selent J, Pastor M, Sandberg K, Heras M, Dantas AP. Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17{beta}-estradiol. Hypertension 56: 405–411, 2010.
35. Ogalla E, Claro C, Alvarez de Sotomayor M, Herrera MD, Rodriguez-Rodriguez R. Structural, mechanical and myogenic properties of small mesenteric arteries from ApoE KO mice: characterization and effects of virgin olive oil diets. Atherosclerosis 238: 55–63, 2015.
36. Onetti Y, Dantas AP, Pérez B, Cugota R, Chamorro A, Planas AM, Vila E, Jiménez-Altayó F. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol 308: H862–H874, 2015.
37. Parastatidis I, Weiss D, Joseph G, Taylor WR. Overexpression of catalase in vascular smooth muscle cells prevents the formation of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 33: 2389–2396, 2013.
38. Peshavariya HM, Chan EC, Liu GS, Jiang F, Dusting GJ. Transforming growth factor-β1 requires NADPH oxidase 4 for angiogenesis in vitro and in vivo. J Cell Mol Med 18: 1172–1183, 2014.
39. Pyeritz RE, Loeys B. The 8th international research symposium on the Marfan syndrome and related conditions. Am J Med Genet A 158: 42–49, 2012.
40. Radermacher KA, Wingler K, Langhauser F, Altenhofer S, Kleikers P, Hermans JJ, Hrabede Angelis M, Kleinschnitz C, Schmidt HH. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal 18: 1418–1427, 2013.
41. Reinhardt DP, Chalberg SC, Sakai LY. The structure and function of fibrillin. Ciba Found Symp 192: 128–143, 1995.
42. Schroder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110: 1217–1225, 2012.
43. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Fórró L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105–114, 2007.
44. Sutliff RL, Hilenski LL, Amanso AM, Parastatidis I, Dikalova AE, Hansen L, Datla SR, Long JS, El-Ali AM, Joseph G, Gleason RL Jr, Taylor WR, Hart CM, Griendling KK, Lassègue B. Polymerase delta interacting protein 2 sustains vascular structure and function. Arterioscler Thromb Vasc Biol 33: 2154–2161, 2013.
45. Syyong HT, Chung AW, van Breemen C. Marfan syndrome decreases Ca2+ wave frequency and vasoconstriction in murine mesenteric resistance arteries without changing underlying mechanisms. J Vasc Res 48: 150–162, 2011.
46. Syyong HT, Chung AW, Yang HH, van Breemen C. Dysfunction of endothelial and smooth muscle cells in small arteries of a mouse model of Marfan syndrome. Br J Pharmacol 158: 1597–1608, 2009.
47. Tong XK, Nicolakakis N, Kocharyan A, Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer’s disease. J Neurosci 25: 11165-11174, 2005.
48. van den Berg JS, Limburg M, Hennekam RC. Is Marfan syndrome associated with symptomatic intracranial aneurysms? Stroke 27: 10–12, 1996.
49. Wityk RJ, Zanferrari C, Oppenheimer S. Neurovascular complications of Marfan syndrome: a retrospective, hospital-based study. Stroke 33: 680–684, 2002.
50. Yang HH, van Breemen C, Chung AW. Vasomotor dysfunction in the thoracic aorta of Marfan syndrome is associated with accumulation of oxidative stress. Vascul Pharmacol 52: 37–45, 2010.
51. Zhou RH, Vendrov AE, Tchivilev I, Niu XL, Molnar KC, Rojas M, Carter JD, Tong H, Stouffer GA, Madamanchi NR, Runge MS. Mitochondrial oxidative stress in aortic stiffening with age: the role of smooth muscle cell function. Arterioscler Thromb Vasc Biol 32: 745–755, 2012.